Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Negatively charged bacterial membrane components and cell surface structures encompass a variety of anionic molecules that define the bacterial envelope's integrity and electrochemical properties. In Gram-negative bacteria, the primary component is lipopolysaccharide (LPS), which contains negatively charged phosphate groups in its lipid A and core polysaccharide regions (Velkov et al., 2013, PMID: 24051210). Gram-positive bacteria utilize teichoic and lipoteichoic acids, which are anionic polymers that extend through the peptidoglycan layer (Swoboda et al., 2010, PMID: 19911871). These structures are essential for maintaining the permeability barrier and sequestering divalent cations like Mg2+ and Ca2+ that stabilize the membrane. Because mammalian cell membranes are primarily composed of zwitterionic phospholipids, the high negative charge density of bacterial surfaces provides a selective target for cationic antimicrobial agents. Drugs such as polymyxins and daptomycin bind to these anionic sites via electrostatic interactions, leading to the displacement of stabilizing ions and subsequent membrane disruption (Humphries et al., 2011, PMID: 22037441). This disruption results in the leakage of intracellular contents, loss of membrane potential, and rapid bacterial cell death. Resistance often involves the enzymatic modification of these components, such as the addition of 4-amino-L-arabinose to LPS, which reduces the net negative charge and decreases drug affinity.
Electrostatic binding of cationic drug molecules to anionic surface components, leading to displacement of divalent cations, membrane permeabilization, and cell lysis.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Negatively charged bacterial membrane components and cell surface structures.